CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T-cell lymphoma

Phillip Ruiz, Sylvain Mailhot, Patricia Delgado, Alexandra Amador, Ana L. Viciana, Luis Ferrer, Natalia Zacharievich

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


The transmembrane serine aminopeptidase dipeptidyl peptidase IV (DPP IV) (also known as CD26) participates in several immunological functions and has a binding affinity for several molecules, including collagen, which may be an integral mechanism for T cells to traverse endothelial barriers. Since CD26 is phenotypically expressed in certain T-cell malignancies, this study utilized a novel four-color cytofluorographic procedure to measure DPP IV enzymatic activity concurrently with the expression of other surface markers in an aggressive hepatosplenic T-cell lymphoma. Immunophenotypic analysis by flow cytometry revealed the tumor to be CD2+, CD3+, CD5-, CD7+, TcR-γ/δ+, CD4-, CD8± CD56+, and CD11c+. The CD26 molecule was also expressed, and DPP IV activity was present, with the maximal activity detectable after 10 min of incubation. These results represent the initial description of enzymatically active CD26 in a T-cell malignancy, and raise the possibility that this molecule may be a participant in the pathogenetic mechanisms utilized by the neoplastic cells.

Original languageEnglish (US)
Pages (from-to)30-35
Number of pages6
JournalCommunications in Clinical Cytometry
Issue number1
StatePublished - Feb 15 1998


  • CD26
  • Dipeptidyl peptidase IV
  • T-cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Cell Biology
  • Pathology and Forensic Medicine
  • Biophysics
  • Endocrinology


Dive into the research topics of 'CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T-cell lymphoma'. Together they form a unique fingerprint.

Cite this